Mirum Pharmaceuticals (MIRM) Cash & Current Investments (2018 - 2026)

Mirum Pharmaceuticals' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $386.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 39.11% year-over-year to $386.3 million; the TTM figure through Mar 2026 stood at $386.3 million (up 39.11% YoY), while the FY2025 annual figure was $383.3 million, up 36.54% from the prior year.
• Cash & Current Investments was $386.3 million for Q1 2026 at Mirum Pharmaceuticals, up from $383.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $434.9 million in Q3 2022 to a low of $125.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $298.4 million across 5 years, with a median of $302.8 million in 2024.
• Biggest YoY gain for Cash & Current Investments was 164.06% in 2023; the steepest drop was 60.4% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $251.7 million in 2022, then advanced by 13.75% to $286.3 million in 2023, then slipped by 1.95% to $280.7 million in 2024, then jumped by 36.54% to $383.3 million in 2025, then climbed by 0.76% to $386.3 million in 2026.
• The last three Cash & Current Investments figures came in at $386.3 million (Q1 2026), $383.3 million (Q4 2025), and $375.5 million (Q3 2025), per Business Quant data.